Rekombinanter CD79B (Polatuzumab Biosimilar) Antikörper

Produktnummer ABIN7795113

Der Humanized Monoklonal Anti-CD79B (Polatuzumab Biosimilar) Antikörper wurde für FACS und in vivo validiert. Er ist geeignet, CD79B (Polatuzumab Biosimilar) in Proben von Human zu detektieren.

Kurzübersicht für Rekombinanter CD79B (Polatuzumab Biosimilar) Antikörper (ABIN7795113)

Target: CD79B (Polatuzumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Humanized

Klonalität: Monoklonal

Konjugat: Dieser CD79B (Polatuzumab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Güteklasse: Research Grade

Produktdetails anti-CD79B (Polatuzumab Biosimilar) Antikörper

Expressionssystem: Mammalian cells

Verwendungszweck: Polatuzumab Biosimilar, Human CD79B Monoclonal Antibody

Produktmerkmale: What is polatuzumab biosimilar research grade? Polatuzumab is a humanized IgG1-kappa monoclonal antibody against the human CD79B protein, which is ubiquitously expressed on the surface of malignant B cells. Polatuzumab vedotin is used to treat diffuse large B-cell lymphoma (DLBCL) after at least two other cancer treatments did not work or have stopped working. It is given in combination with bendamustine (Bendeka, Treanda) and a medicine that contains rituximab (Rituxan). Polatuzumab vedotin works by attaching to CD79b and releasing a toxic substance that kills the cancer cells. Polatuzumab biosimilar uses the same protein sequences as the therapeutic antibody polatuzumab.

Aufreinigung: Protein A or G affinity column

Reinheit: >95 % by reducing SDS-PAGE

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human CD79B

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: > 3 mg/mL

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Details zu CD79B (Polatuzumab Biosimilar)

Target: CD79B (Polatuzumab Biosimilar)

Andere Bezeichnung: Polatuzumab Biosimilar

Substanzklasse: Biosimilar